Intra-arterial versus intravenous chemoradiation for advanced head and neck cancer: Results of a randomized phase 3 trial

Cancer

Volumn 116, Issue 9, 2010, Pages 2159-2165

  Rasch, Coen R N ^a   Hauptmann, Michael ^a   Schornagel, Jan ^a   Wijers, Oda ^b   Buter, Jan ^c   Gregor, Theo ^d   Wiggenraad, Ruud ^e   De Boer, Jan Paul ^a   Ackerstaff, Annemiek H ^a   Kroger, Robert ^a   Hoebers, Frank J P ^a   Balm, Alfons J M ^a,f  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b Radiotherapy Institute Friesland   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d WAIKATO HOSPITAL   (New Zealand)

^e MEDICAL CENTER HAAGLANDEN   (Netherlands)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Cisplatin; Head and neck cancer; Intra arterial chemotherapy; Radiotherapy; Randomized clinical trial

Indexed keywords

CISPLATIN; SODIUM THIOSULFATE;

ADULT; ARTICLE; BLOOD TOXICITY; BRAIN TOXICITY; CARDIOTOXICITY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ESOPHAGUS CARCINOMA; FEMALE; FOLLOW UP; HEAD AND NECK CANCER; HEARING LOSS; HUMAN; KIDNEY INJURY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; OTOTOXICITY; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; TUBE FEEDING; TUMOR VOLUME;

COMBINED MODALITY THERAPY; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS, SQUAMOUS CELL; PATIENT COMPLIANCE;

EID: 77951463319     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24916     Document Type: Article

References (19)

1. Pignon JP, le Maître, Bourhis J. Meta-analyses of chemotherapy in head and neck cancer (MACH-NC): an update. Int J Radiat Oncol Biol Phys. 2007;69(suppl 2):S112-S114. (Pubitemid 47369400)
2. van de Vaart P, Belderbos J, de Jong D, et al. DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy. Int J Cancer. 2000;89:160-166. (Pubitemid 30185925)
3. Los G, Blommaert A, Barton R, et al. Selective intra-arterial infusion of high-dose cisplatin in patients with advanced head and neck cancer results in high tumor platinum concentrations and cisplatin-DNA adduct formation. Cancer Chemother Pharmacol. 1995;37:150-154.
4. Robbins KT, Kumar P, Regine WF, et al. Efficacy of targeted supradose cisplatin and concomitant radiation therapy for advanced head and neck cancer: the Memphis experience. Int J Radiat Oncol Biol Phys. 1997;38:263-271. (Pubitemid 27318641)
5. Robbins KT, Fontanesi J, Wong FS, et al. A novel organ preservation protocol for advanced carcinoma of the larynx and pharynx. Arch Otolaryngol Head Neck Surg. 1996;122:853-857. (Pubitemid 26271764)
6. Balm AJ, Rasch CR, Schornagel JH, et al. High-dose superselective intra-arterial cisplatin and concomitant radiation (RADPLAT) for advanced head and neck cancer. Head Neck. 2004;26:485-493. (Pubitemid 38702635)
7. Hoebers FJ, Heemsbergen W, Balm AJ, et al. Concurrent chemoradiation with daily low dose cisplatin for advanced stage head and neck carcinoma. Radiother Oncol. 2007;85:42-47. (Pubitemid 47570059)
8. Ackerstaff AH, Balm AJ, Rasch CR, et al. First-year quality of life assessment of an intra-arterial (RADPLAT) versus intravenous chemoradiation Phase III trial. Head Neck. 2009;31:77-84.
9. Common Toxicity Criteria, Version 2.0 DCTD, NCI, NIH, DHHS Cancer Therapy Evaluation Program 35 Revised March 23, 1998: 2008 update. Available at: http://ctep.cancer.gov/forms/. Accessed February 17, 2010
10. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350:1937-1944.
11. Rabbani A, Hinerman RW, Schmalfuss IM, et al. Radiotherapy and concomitant intraarterial cisplatin (RADPLAT) for advanced squamous cell carcinomas of the head and neck. Am J Clin Oncol. 2007;30:283-286. (Pubitemid 46884149)
12. Brizel DM. Radiotherapy and concurrent chemotherapy for the treatment of locally advanced head and neck squamous cell carcinoma. Semin Radiat Oncol. 1998;8:237-246. (Pubitemid 28460808)
13. van den Broek GB, Balm AJ, Van den Brekel MW, et al. Relationship between clinical factors and the incidence of toxicity after intra-arterial chemoradiation for head and neck cancer. Radiother Oncol. 2006;81:143-150.
14. Hoebers FJ, Pluim D, Hart AA, et al. Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor. Cancer Chemother Pharmacol. 2007;61:1075-1081. (Pubitemid 351423118)
15. van den Broek GB, Rasch CR, Pameijer FA, et al. Pretreatment probability model for predicting outcome after intraarterial chemoradiation for advanced head and neck carcinoma. Cancer. 2004;101:1809-1817.
16. Robbins KT, Kumar P, Harris J, et al. Supradose intra-arterial cisplatin and concurrent radiation therapy for the treatment of stage IV head and neck squamous cell carcinoma is feasible and efficacious in a multi-institutional setting: results of Radiation Therapy Oncology Group Trial 9615. J Clin Oncol. 2005;23:1447-1454. (Pubitemid 46260032)
17. Kumar P, Robbins KT. Treatment of advanced head and neck cancer with intra-arterial cisplatin and concurrent radiation therapy: the "RADPLAT" protocol. Curr Oncol Rep. 2001;3:59-65.
18. Robbins KT, Doweck I, Samant S, et al. Factors predictive of local disease control after intra-arterial concomitant chemoradiation (RADPLAT). Laryngoscope. 2004;114:411-417. (Pubitemid 38391901)
19. Robbins KT, Storniolo AM, Kerber C, et al. Phase I study of highly selective supradose cisplatin infusions for advanced head and neck cancer. J Clin Oncol. 1994;12:2113-2120. (Pubitemid 2152754)